Market News & Trends
Vector Pharma & Oncopeptides FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East & North Africa
Oncopeptides AB and Vector Pharma FZCO recently announced a collaboration to commercialize Oncopeptides’ flagship drug Pepaxti (melphalan flufenamide) in the Middle….
Vaccinex Announces $1.5-Million Registered Direct Offering & Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Vaccinex, Inc. recently announced it has entered into definitive agreements with certain institutional investors for the purchase and sale of 193,000 shares of its common stock in a….
LIXTE's Lead Clinical Compound Can Force Cancer Cells to Give Up Their Cancer-Causing Properties
LIXTE Biotechnology Holdings, Inc. recently announced publication of preclinical data in the online journal, Cancer Discovery, showing its lead clinical compound, LB-100, can force cancer…
Tellbio’s Technology Demonstrates Analysis of Circulating Tumor Cells Can Predict Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Radium-223
TellBio, Inc. recently announced publication of data that shows the promise of CTCs as a prognostic biomarker for patients with prostate cancer receiving novel therapies…
Vetter Earns Prestigious Honors Across All Core Categories in the 13th Annual CDMO Leadership Awards
Vetter once again earned the 2024 CDMO Leadership Awards in all six core categories – quality, expertise, reliability, capabilities, compatibility and service for big pharma,…
Intravacc Announces Positive Data of First in Human Intranasal OMV-Based Vaccine for SARS-CoV-2
Intravacc recently announced positive clinical data of a first in human (FIH) study of Avacc 10, an intranasal outer membrane vesicles (OMV) based booster vaccine…
Teva UK & Closed Loop Medicine Announce Strategic Partnership to Advance Development of Personalized Medicines
Teva UK Limited and Closed Loop Medicine Ltd have announced a strategic partnership to advance the development of personalized medicine. Under the agreement, Closed Loop Medicine and Teva UK will investigate….
Nanoscope Therapeutics Announces Positive Top-line Results From Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa
Nanoscope Therapeutics Inc. recently announced positive top-line results after the completion of the 2-year Phase 2b RESTORE randomized, controlled clinical trial of its lead program, MCO-010,…
Exothera Pledges to Fast-Track RNA Therapies With Expansion of World-First Continuous-Batch RNA Manufacturing Solution Into North America
Game-changing continuous-batch production of RNA service removes process development and scale-up steps through automation and significantly cuts clinical development time, while enhancing quality and yield….
AcedrA Biopharmaceuticals & Essential Pharma Sign Distribution Agreement to Commercialize Essential Medicines in the Middle East & North Africa Region
Essential Pharma recently announced it has signed a Distribution Agreement with AcedrA BioPharmaceuticals. This strategic collaboration aims to address unmet commercial and medical needs by….
Opus Genetics Announces Completion of Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy in Patients with Rare Inherited Retinal Disease LCA5
Opus Genetics recently announced the first cohort has completed dosing in its open-label, dose-escalation Phase 1/2 clinical trial evaluating the subretinal delivery of OPGx-LCA5, an…
Bio-Rad Launches Validated Antibodies for Rare Cell & Circulating Tumor Cell Enumeration
Bio-Rad Laboratories, Inc. recently announced the launch of validated antibodies for rare cell and circulating tumor cell (CTC) enumeration. Validated for use with Bio-Rad’s Celselect…
Verge Genomics & Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy
Verge Genomics and Ferrer recently announced a strategic collaboration to co-develop VRG50635, Verge’s lead drug candidate, for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis….
Imbria Pharmaceuticals Presents Results From IMPROVE-HCM Trial of Ninerafaxstat
Imbria Pharmaceuticals, Inc. recently announced the results from the Phase 2 IMPROVE-HCM clinical trial, evaluating ninerafaxstat, a novel cardiac mitotrope and partial fatty acid oxidation…
TFF Pharmaceuticals Announces Interim Data From Phase 2 Study of Tacrolimus Inhalation Powder
TFF Pharmaceuticals, Inc. recently announced the acceptance of its late-breaking clinical science abstract for oral presentation at the 44th Annual International Society for Heart and…
Bluejay Announces Receipt of PRIME Designation From EMA for Chronic Hepatitis Delta Virus Infection Treatment
Bluejay Therapeutics, Inc. recently announced the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to BJT-778 for the treatment of Chronic Hepatitis Delta…
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
IGC Pharma, Inc. recently announced the results of an interim analysis of its ongoing Phase 2 trial investigating IGC-AD1 as a treatment for Agitation in…
Pace Life Sciences Adds Liquid Capsule Filling Technology, Acquires New Jersey Laboratory From Curia & Appoints Dawn Von Rohr as Division President
Pace Life Sciences makes three major announcements for expansion of services, key acquisition, and new division Vice President….
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits From Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer
Nykode Therapeutics ASA recently announced key conclusions from the updated analysis from the Phase 2 VB-C-02 trial. The trial investigates the use of Nykode’s wholly…
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study for Potential First-in-Class Therapeutic for Urea Cycle Disorders
Lead program in urea cycle disorders highlights power of CAMP4’s RAP Platform to increase gene expression using programmable, targeted medicines, with clinical candidate moving from screen-to-clinic within 3 years….
